About this item:

38 Views | 26 Downloads

Author Notes:

Correspondence: Giselle S. Mosnaim, MD, MS, 1001 University Place, Evanston, IL 60201.

Disclosures: P. Bansal has served on the advisory boards for Genentech, Regeneron, Kaleo, AstraZeneca, ALK, Shire, Takeda, Pharming, CSL Behring, and Teva; is the speaker for AstraZeneca, Regeneron, ALK, Takeda, Shire, CSL Behring, Takeda, and Pharming; and has served as an independent consultant for ALK, AstraZeneca, and Exhale.

G. S. Mosnaim has received research grant support from AstraZeneca and GlaxoSmithKline; currently receives research grant support from Propeller Health; owned stock in Electrocore; and has served as a consultant and/or member of a scientific advisory board for GlaxoSmithKline, Sanofi-Regeneron, Teva, Novartis, Astra Zeneca, Boehringer Ingelheim, and Propeller Health.

The rest of the authors declare that they have no relevant conflicts of interest.


Research Funding:

No funding was received for this work.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Allergy
  • Immunology
  • Telemedicine
  • Coding
  • Billing
  • Telehealth
  • allergy
  • Asthma
  • Patient

Work Group Report: COVID-19: Unmasking Telemedicine

Show all authors Show less authors


Journal Title:

Journal of Allergy and Clinical Immunology - In Practice


Volume 8, Number 8


, Pages 2461-+

Type of Work:

Article | Final Publisher PDF


Telemedicine adoption has rapidly accelerated since the onset of the COVID-19 pandemic. Telemedicine provides increased access to medical care and helps to mitigate risk by conserving personal protective equipment and providing for social/physical distancing to continue to treat patients with a variety of allergic and immunologic conditions. During this time, many allergy and immunology clinicians have needed to adopt telemedicine expeditiously in their practices while studying the complex and variable issues surrounding its regulation and reimbursement. Some concerns have been temporarily alleviated since March 2020 to aid with patient care in the setting of COVID-19. Other changes are ongoing at the time of this publication. Members of the Telemedicine Work Group in the American Academy of Allergy, Asthma & Immunology (AAAAI) completed a telemedicine literature review of online and Pub Med resources through May 9, 2020, to detail Pre-COVID-19 telemedicine knowledge and outline up-to-date telemedicine material. This work group report was developed to provide guidance to allergy/immunology clinicians as they navigate the swiftly evolving telemedicine landscape.

Copyright information:

© 2020 American Academy of Allergy, Asthma & Immunology

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote